Jacobs Levy Equity Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-65,923
| Closed | -$7.31M | – | 1019 |
|
|
2025
Q2 | $7.31M | Sell |
65,923
-56,451
| -46% | -$6.01M | 0.03% | 358 |
|
|
2025
Q1 | $13.7M | Sell |
122,374
-526,012
| -81% | -$54.3M | 0.05% | 285 |
|
|
2024
Q4 | $59.9M | Buy |
648,386
+140,095
| +28% | +$12.6M | 0.21% | 113 |
|
|
2024
Q3 | $42.6M | Sell |
508,291
-459,881
| -47% | -$35.1M | 0.16% | 150 |
|
|
2024
Q2 | $66.4M | Buy |
968,172
+450,402
| +87% | +$30.1M | 0.27% | 87 |
|
|
2024
Q1 | $37.9M | Buy |
517,770
+390,301
| +306% | +$30M | 0.17% | 136 |
|
|
2023
Q4 | $10.3M | Sell |
127,469
-472
| -0.4% | -$36.7K | 0.05% | 299 |
|
|
2023
Q3 | $9.59M | Sell |
127,941
-65,536
| -34% | -$5.04M | 0.06% | 264 |
|
|
2023
Q2 | $14.9M | Buy |
193,477
+99,805
| +107% | +$7.96M | 0.09% | 235 |
|
|
2023
Q1 | $7.77M | Buy |
93,672
+79,342
| +554% | +$6.57M | 0.05% | 323 |
|
|
2022
Q4 | $1.23M | Sell |
14,330
-932,656
| -98% | -$73.9M | 0.01% | 648 |
|
|
2022
Q3 | $58.4M | Sell |
946,986
-1,437,144
| -60% | -$90.6M | 0.46% | 48 |
|
|
2022
Q2 | $147M | Sell |
2,384,130
-88,239
| -4% | -$5.46M | 1.14% | 8 |
|
|
2022
Q1 | $147M | Buy |
2,472,369
+495,476
| +25% | +$31.7M | 0.99% | 11 |
|
|
2021
Q4 | $144M | Buy |
1,976,893
+401,998
| +26% | +$27.7M | 0.96% | 12 |
|
|
2021
Q3 | $110M | Sell |
1,574,895
-588,194
| -27% | -$41.3M | 0.74% | 21 |
|
|
2021
Q2 | $149M | Buy |
2,163,089
+254,884
| +13% | +$17M | 1.01% | 7 |
|
|
2021
Q1 | $123M | Buy |
1,908,205
+62,701
| +3% | +$4.04M | 0.95% | 10 |
|
|
2020
Q4 | $108M | Buy |
1,845,504
+458,871
| +33% | +$27.7M | 0.94% | 7 |
|
|
2020
Q3 | $87.6M | Buy |
1,386,633
+10,922
| +0.8% | +$757K | 0.91% | 12 |
|
|
2020
Q2 | $106M | Buy |
1,375,711
+74,839
| +6% | +$5.74M | 1.15% | 6 |
|
|
2020
Q1 | $97.3M | Sell |
1,300,872
-294,040
| -18% | -$20.3M | 1.25% | 7 |
|
|
2019
Q4 | $104M | Buy |
1,594,912
+474,692
| +42% | +$30.9M | 1.02% | 9 |
|
|
2019
Q3 | $71M | Buy |
1,120,220
+731,855
| +188% | +$47.8M | 0.87% | 10 |
|
|
2019
Q2 | $26.2M | Buy |
388,365
+174,475
| +82% | +$11.5M | 0.36% | 64 |
|
|
2019
Q1 | $13.9M | Buy |
213,890
+189,460
| +776% | +$12.6M | 0.2% | 127 |
|
|
2018
Q4 | $1.53M | Buy |
+24,430
| New | +$1.71M | 0.03% | 521 |
|
|
2017
Q4 | – | Sell |
-122,998
| Closed | -$9.96M | – | 1017 |
|
|
2017
Q3 | $9.96M | Sell |
122,998
-189,656
| -61% | -$14.5M | 0.19% | 165 |
|
|
2017
Q2 | $22.1M | Sell |
312,654
-236,100
| -43% | -$15.7M | 0.47% | 52 |
|
|
2017
Q1 | $37.3M | Sell |
548,754
-24,430
| -4% | -$1.72M | 0.75% | 11 |
|
|
2016
Q4 | $41M | Sell |
573,184
-103,020
| -15% | -$7.66M | 0.79% | 11 |
|
|
2016
Q3 | $53.5M | Buy |
676,204
+157,850
| +30% | +$12.8M | 0.96% | 8 |
|
|
2016
Q2 | $43.2M | Sell |
518,354
-27,190
| -5% | -$2.41M | 0.9% | 9 |
|
|
2016
Q1 | $50.1M | Sell |
545,544
-67,429
| -11% | -$6.08M | 1.06% | 5 |
|
|
2015
Q4 | $62M | Sell |
612,973
-10,850
| -2% | -$1.13M | 1.23% | 4 |
|
|
2015
Q3 | $61.3M | Sell |
623,823
-6,010
| -1% | -$667K | 1.26% | 3 |
|
|
2015
Q2 | $73.7M | Sell |
629,833
-110,267
| -15% | -$12M | 1.4% | 2 |
|
|
2015
Q1 | $72.6M | Buy |
740,100
+9,050
| +1% | +$919K | 1.24% | 4 |
|
|
2014
Q4 | $68.9M | Buy |
731,050
+165,794
| +29% | +$17.1M | 1.18% | 7 |
|
|
2014
Q3 | $60.2M | Buy |
+565,256
| New | +$55.3M | 1.01% | 8 |
|
Other funds holding GILD
Jacobs Levy Equity Management's GILD Position: Q3 2025 in Review
Jacobs Levy Equity Management sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 65,923 shares — an estimated $7.31M sold.
Jacobs Levy Equity Management first reported a position in GILD in Q3 2014 and held it in 40 quarters. The position peaked at $149M in Q2 2021. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.
- Jacobs Levy Equity Management reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
- Jacobs Levy Equity Management sold 65,923 Gilead Sciences shares in Q3 2025, an estimated $7.31M.
- Jacobs Levy Equity Management first reported a position in Gilead Sciences in Q3 2014 and held it in 40 quarters.
- Jacobs Levy Equity Management's Gilead Sciences position peaked at $149M in Q2 2021.
- 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.